ERT Expands Suite of eCOA Offerings to Include Bring Your Own Device (BYOD) Solution
DIARYpro Available on Patients' Smartphones - Delivering Reliability while Reducing Trial Costs
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced an expansion to its comprehensive suite of electronic Clinical Outcome Assessment (eCOA) data collection solutions for use in clinical trials. With this expansion, clinical trial sponsors can improve trial efficiencies while reliably collecting important eCOA data via patients’ personal Apple® (iOS) or Android™ phones and tablets.
An extension of ERT’s flagship DIARYpro® solution, the Bring Your Own Device (BYOD) option is based on over 25 years of scientifically and regulatory-proven COA data collection experience. This native mobile application enables trial sponsors to acquire high-quality eCOA data while eliminating the cost and time associated with purchasing, shipping, and managing a global fleet of dedicated eCOA devices. In addition, ERT’s BYOD solution ensures that assessments are presented consistently across different device types and screen resolutions.
“DIARYpro has set the industry standard for high data quality and reliability,” said Bob Young, EVP and Product Line Executive, eCOA at ERT. “In expanding the solution to include a BYOD option, we conducted significant research among global clinical trial sponsors to ensure it not only meets these standards, but also offers valuable features that will streamline the eCOA data collection process.”
Unlike other mobile applications that run within web browsers and require a live internet connection, ERT’s BYOD solution allows fully-offline operation for when data must be entered during strict time windows, regardless of internet connectivity. Further, on-device reminders to begin or continue assessments are not dependent on any external email or text server, and these notifications blend naturally into smartphone users’ daily lives, enhancing compliance.
Having supported over 1,200 COA global clinical trials to date, ERT’s solutions and services are routinely relied upon by biopharmaceutical researchers for capturing important patient data during clinical development. For more information on ERT’s comprehensive suite of eCOA data collection solutions, including BYOD, visit www.ert.com/eCOA.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
